The human microbiome, the community of trillions of microorganisms living in and on the body, plays an important role in digestion, immunity and metabolic health. Disruption of this community has been linked to conditions such as recurrent Clostridioides difficile infection, inflammatory bowel disease, metabolic disorders and even response to cancer immunotherapy. This has given rise to a new class of products known as live biotherapeutic products (LBPs) and other microbiome-based therapeutics. Developing and manufacturing these products is a novel challenge, because the active ingredient is a living organism. This white paper reviews the scientific and operational hurdles from strain selection to GMP production.
Understanding Microbiome-Based Therapeutics
Microbiome therapeutics include live biotherapeutic products, which contain live organisms such as bacteria intended to prevent, treat or cure a disease, as well as fecal microbiota-derived products and defined consortia. They differ from probiotics, which are generally marketed as foods or supplements, in that LBPs are developed and regulated as drugs with demonstrated clinical efficacy.
Product Types
- •Single-strain live biotherapeutics
- •Defined multi-strain consortia
- •Donor-derived microbiota preparations
- •Engineered bacteria designed to express therapeutic functions
Strain Selection and Banking
Selecting the Right Organism
Candidate strains are identified through analysis of healthy versus diseased microbiomes, functional screening and mechanistic studies. Selection criteria include safety, absence of antibiotic resistance transfer, genetic stability, efficacy in models and manufacturability. Whole-genome sequencing confirms identity and screens for virulence factors.
Cell Banking
A master cell bank and working cell banks, produced under GMP, ensure consistent starting material. Banks are characterized for identity, purity, viability and genetic stability. Preservation conditions and cryoprotectants are optimized to maintain viability, particularly for oxygen-sensitive anaerobes.
Fermentation and Downstream Processing
Upstream Cultivation
Many gut commensals are strict anaerobes, requiring specialized equipment, anaerobic gas mixtures and careful media design. Growth rates and yields may be lower than for traditional industrial microbes, and process control must preserve physiological state. Media components must be free of problematic animal-derived materials or fully controlled.
Harvest, Concentration and Stabilization
Cells are harvested by centrifugation or filtration, concentrated and mixed with cryoprotectants before freezing or freeze-drying. Lyophilization requires cycle development tailored to each strain, balancing viability with stability. Spray drying and other approaches are also explored for cost and scale.
Preventing Contamination
Because the product is not terminally sterilized and contains living organisms, aseptic technique and environmental control are critical. Cross-contamination between strains and facility containment need careful design. Facility segregation prevents cross-contamination with other products.
Potency, Characterization and Release Testing
Defining Potency
Potency assays for LBPs must reflect biological activity. Viable cell count by colony-forming units is a foundational measure, but functional assays, such as metabolite production or immune cell activation, may be needed to correlate with clinical effect. Developing and qualifying potency assays early is vital.
Other Quality Attributes
Release testing includes identity, purity, absence of adventitious agents, microbial limits, strain ratio for consortia and viability. Rapid methods such as flow cytometry, qPCR and next-generation sequencing complement culture-based methods, which can be slow for slow-growing anaerobes.
Consistency and Comparability
Demonstrating consistency across lots and comparability after process changes requires well-characterized products and orthogonal assays. Genetic stability monitoring across generations is a safety consideration.
Stability and Formulation
Preserving Viability
Viability declines over time and under stress from moisture, oxygen and temperature. Protective excipients, low-moisture packaging and oxygen barriers extend shelf life. Stability studies track viable count, potency and physical attributes.
Delivery to the Gut
Oral products must survive gastric acid and bile to reach the intestinal target. Enteric-coated capsules, microencapsulation and delayed-release technologies protect organisms. For some indications, enema or colonoscopic delivery may be used. Dosage form selection influences patient acceptance.
Regulatory Landscape
Regulators in the United States and Europe have issued guidance on LBP development, addressing CMC, nonclinical and clinical considerations. Expectations include thorough product characterization, safety assessment such as screening for antibiotic resistance, and careful clinical monitoring. For donor-derived products, donor screening and traceability are essential. Early interaction with regulators clarifies requirements for each product type.
Clinical Development Considerations
Trial design must account for variability in baseline microbiomes, prior antibiotic use and diet. Pharmacodynamic endpoints include engraftment and microbiome shifts, measured using sequencing. Safety monitoring includes the potential for translocation in vulnerable patients.
Scale-Up and Partner Selection
Few manufacturing sites have experience with anaerobic GMP production. Selecting partners with LBP expertise, dedicated suites and relevant analytics reduces risk. Technology transfer must preserve strain physiology, since scale-up may alter growth behavior.
Conclusion
Microbiome-based therapeutics offer a novel treatment paradigm, but they require specialized approaches to strain selection, fermentation, analytics and formulation. By addressing these challenges systematically and working closely with regulators and experienced partners, developers can bring this promising modality to patients.
About This White Paper
This white paper is published by Biotechnology Media Insights Editorial and curated by Biotechnology Media Insights, a trusted source for pharmaceutical and biotechnology research, technical guides and industry analysis.